Remote Ischaemic Preconditioning in Transplantation (RIPTRANS)
ConditionTransplant Dysfunction
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHelsinki University Central Hospital
About this trial
Remote ischemic preconditioning (RIPC) is a concept where remotely induced ischemia produces protection against ischemia-reperfusion injury in a remote organ. RIPC has been studied extensively in animal models and heart surgery, but it's benefit in transplantation has been studied less. The primary aim of this study is to find out whether RIPC performed in a donor in donation after brain-death (DBD) could improve delayed graft function rate of kidney transplants.
Eligibility criteria
Qualifiers
Brain-dead organ donor with a plan of harvesting at least one kidney
Disqualifiers
Haemodynamically unstable donor
Age below 18 years
Planned organ recipients are recruited to another prospective trial, which prevents participation in this trial.
Trial design
Treatments tested in this trial
- RIPC
- Sham-RIPC
Treatment groups
496 Participants
are divided into 2 treatment groupsSponsors and collaborators
Helsinki University Central Hospital
Lead sponsor
Finska Läkaresällskapet (funding)
Collaborator
Academy of Finland
Collaborator
Helsinki University Hospital Research Funds (funding)
Collaborator
Source ClinicalTrials.gov